#Canada #Saskatoon #ZYUS Life Sciences #Trichomylin #UTOPIA-1

ZYUS Life Sciences Initiates Phase 2a UTOPIA-1 Cancer Pain Trial

ZYUS Life Sciences Corporation (TSXV: ZYUS), a clinical-stage entity dedicated to advancing innovative, non-opioid pain management solutions, proudly announces the activation of its first clinical site and the enrollment of its initial patient in the Phase 2a UTOPIA-1 trial. This significant milestone reflects ZYUS' commitment to addressing the critical medical needs of patients suffering from cancer-related pain.

Overview of the UTOPIA-1 Trial

The UTOPIA-1 trial, which stands for Unique Treatment of Oncology Pain in Advanced Cancer, is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary effectiveness of Trichomylin® softgel capsules. These capsules aim to provide relief to individuals with advanced cancer experiencing moderate to severe pain associated with their condition. The primary focus is to explore how Trichomylin can serve as a viable alternative to traditional pain management therapies generall, including opioids.

The Centre Hospitalier de l'Université de Montréal (CHUM) has been selected as the trial's inaugural clinical site, having successfully enrolled the first patient and actively recruiting more participants to enhance the study's robustness. This early progress underscores a foundational step in ZYUS' broader clinical development agenda, paving the way for more effective treatments in oncology pain management.

Importance of This Development

Brent Zettl, the President and CEO of ZYUS Life Sciences, expressed enthusiasm regarding this pivotal moment, stating, "Activating our first site and enrolling the first patient represents a significant step forward in advancing UTOPIA-1." He noted that Trichomylin softgels are crafted to bridge the existing treatment gap between current options like opioids and NSAIDs, representing a groundbreaking, evidence-based approach to pain alleviation.

This trial aims not just to generate data but to assess how innovative therapies like Trichomylin can lead to better patient outcomes, ultimately creating long-term value for stakeholders in the company.

The Vision of ZYUS Life Sciences

ZYUS Life Sciences is at the forefront of developing cannabinoid-based pharmaceutical drug candidates aimed at improving pain management practices. With unwavering dedication to regulatory compliance and intellectual property protection, ZYUS is focused on bringing forward therapies that address significant unmet medical needs. Their endeavors contribute not only to patient health but also work towards establishing a robust shareholder value.

For anyone interested in learning more about the UTOPIA-1 trial’s details, visit clinicaltrials.gov and refer to the identifier NCT06533657.

In summary, the initiation of the Phase 2a UTOPIA-1 trial marks an important stride for ZYUS Life Sciences. By concentrating on developing non-opioid solutions for cancer pain, they are positioned to make a significant impact in the field of oncology, offering hope to many who suffer from pain that traditional therapies have not adequately addressed. With this progressive step, ZYUS remains committed to ensuring the wellbeing of patients while striving for innovation in pain management therapies.